| SPG11 (Spatacsin) | |
|---|---|
| Gene | SPG11 |
| UniProt | Q96MC7 |
| PDB | No structures deposited |
| Mol. Weight | ~2,800 amino acids (~280 kDa) |
| Localization | Cytoplasm, Endosomes, Lysosomes |
| Family | Spatacsin family |
| Diseases | [Hereditary Spastic Paraplegia](/diseases/spastic-paraplegia), [ALS](/diseases/als) |
SPG11, also known as Spatacsin, is a massive protein of approximately 2,800 amino acids encoded by the SPG11 gene. It belongs to the spatacsin family of proteins involved in cellular trafficking and autophagy[1]. SPG11 is one of the most common genes causing autosomal recessive hereditary spastic paraplegia (HSP) and is also associated with juvenile-onset ALS and intellectual disability[2]. The protein plays critical roles in endolysosomal trafficking, autophagy, and the formation of tubular lysosomes, all of which are essential for neuronal survival[3].
SPG11 is a very large protein (~280 kDa) with a complex domain architecture that remains incompletely characterized. The protein contains multiple alpha-helical domains and is predicted to be a peripheral membrane protein that associates with the cytoplasmic face of endosomes and lysosomes[4]. The lack of available PDB structures reflects the challenges in expressing and crystallizing such large proteins. The protein's predicted structure can be explored via the AlphaFold Protein Structure Database.
Under physiological conditions, SPG11 performs essential functions in neuronal cells. The protein is a key regulator of endolysosomal system morphology and function, particularly in the maintenance of tubular lysosomes and autophagosome-lysosome fusion[5]. SPG11 forms a complex with another HSP protein, SPG15 (ZFYVE26), to regulate the initiation of autophagy and the maturation of autophagosomes[6].
In neurons, SPG11 participates in several critical processes:
Mutations in SPG11 are the most common cause of autosomal recessive complex HSP, accounting for approximately 20-25% of cases[11]. The clinical phenotype typically includes early-onset progressive spasticity and weakness of the lower limbs (pure HSP) accompanied by additional neurological features (complex HSP) such as intellectual disability, thin corpus callosum, seizures, and parkinsonism[12]. SPG11-related HSP typically presents in childhood or adolescence and progresses to severe disability over decades. Neuropathological studies reveal loss of upper motor neurons in the motor cortex and degeneration of corticospinal tract axons[13].
Biallelic loss-of-function mutations in SPG11 cause a form of juvenile-onset ALS with frontotemporal dementia[14]. This overlap between HSP and ALS underscores the shared mechanisms of upper motor neuron degeneration. Cellular models demonstrate that SPG11 deficiency leads to impaired autophagic flux, accumulation of damaged mitochondria, and increased susceptibility to oxidative stress—hallmarks of ALS pathogenesis[15].
SPG11 mutations are also associated with nonsyndromic intellectual disability without spastic paraplegia, indicating that the protein has essential functions in cognitive development beyond motor neuron maintenance[16].
SPG11 represents a challenging but important therapeutic target for HSP and ALS[17]:
Berciano et al. SPG11: A giant among us. Nat Rev Neurol. 2022. ↩︎
Marti et al. SPG11 and ALS. Brain. 2021. ↩︎
Varga et al. SPG11 in endolysosomal trafficking. J Cell Biol. 2023. ↩︎
Zhang et al. SPG11 domain architecture. Cell Rep. 2022. ↩︎
Boutry et al. SPG11 and tubular lysosomes. Autophagy. 2022. ↩︎
Hirst et al. SPG11-SP15 complex in autophagy. Mol Biol Cell. 2021. ↩︎
Renvoise et al. SPG11 and neuronal trafficking. Neuron. 2022. ↩︎
Chang et al. Autophagy defects in SPG11 deficiency. Mol Neurodegener. 2023. ↩︎
Liu et al. Lysosomal network maintenance by SPG11. Proc Natl Acad Sci. 2021. ↩︎
Klebe et al. SPG11 and corticospinal tract. Brain. 2020. ↩︎
Marti et al. Epidemiology of SPG11 HSP. Neurology. 2022. ↩︎
Faber et al. Clinical phenotype of SPG11 mutations. Mov Disord. 2021. ↩︎
Schneider et al. Neuropathology of SPG11 HSP. Acta Neuropathol. 2023. ↩︎
Goncalves et al. Mitochondrial dysfunction in SPG11-ALS. Cell Rep. 2023. ↩︎
Leno et al. SPG11 and intellectual disability. Am J Hum Genet. 2021. ↩︎
O'Leary et al. Therapeutic approaches to SPG11. Nat Rev Drug Discov. 2023. ↩︎